Literature DB >> 35231642

A multicenter cohort study of severe dengue and critically ill influenza patients with elevated cardiac troponin-I: Difference clinical features and high mortality.

Ing-Kit Lee1, Yen-Hsu Chen2, Chung-Hao Huang2, Jui-Chi Hsu3, Yi-Chin Chang3, Hong-Jie Kuo3, Chien-Hsiang Tai3, Nan-Yao Lee4.   

Abstract

BACKGROUND: As cardiac involvement can cause serious complications and death, understanding its role in acute dengue and influenza virus infections is important.
METHODS: We provide a comparative evaluation of severe dengue and critically ill influenza patients with elevated cardiac troponin-I (cTnI) from 2014 to 2019. Inclusion criteria included patients in which cTnI test were ordered. Patient without cTnI test was excluded.
RESULTS: During the study period, 82 (41 severe dengue and 41 critically ill influenza) patients had cTnI elevations, and 81 (35 severe dengue and 46 critically ill influenza) patients had a single normal cTnI test. Severe dengue patients with cTnI elevations had a significantly higher incidences of acute kidney injury, gastrointestinal bleeding, early mortality (≤7 after illness onset) and in-hospital mortality than those with severe dengue and single normal cTnI test. Significantly higher aspartate aminotransferase (AST) levels and higher incidence of gastrointestinal bleeding was observed in critically ill influenza patients with cTnI elevations compared to critically ill influenza patients with single normal cTnI measurement. Of the patients with cTnI elevations, the early and in-hospital mortality rates were 53.6% and 65.8%, respectively, in severe dengue patients, and 7.3% and 46.3%, respectively, in critically ill influenza patients. Significantly higher early mortality rates were observed in severe dengue patients with elevated cTnI levels than in critically ill influenza patients with cTnI elevations. Critically ill influenza patients with elevated cTnI levels had significantly higher incidences of pneumonia, pneumothorax, and bacteremia than severe dengue patients with cTnI elevations. Multivariate analysis revealed elevated AST (>1000U/L) (95% confidence interval [CI]: 1.690-143.174) was an independent risk factor for in-hospital mortality in severe dengue patients with elevated cTnI levels. Leukocytosis (95% CI: 1.079-1.124) and thrombocytopenia (95% CI: 2.739-5.821) were independently correlated with in-hospital mortality in critically ill influenza patients with cTnI elevations.
CONCLUSIONS: Differences in clinical features between severe dengue and critically ill influenza patients with cTnI elevations. High early mortality rate was observed in severe dengue patients with cardiac involvement. In contrast, most critically ill influenza patients died ≥2 weeks after the onset of illness, regardless of cTnI elevations. Our report has important clinical implications for the timely recognition and management of cardiac complication in patients with acute dengue and influenza virus infections.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac involvement; Cardiac troponin-I; Dengue; Influenza

Mesh:

Substances:

Year:  2022        PMID: 35231642     DOI: 10.1016/j.tmaid.2022.102281

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  2 in total

1.  Analysis of the Predictive Effect of Lactic Acid Combined with Cardiac Troponin T and 5-Hydroxytryptophan on the Severity of Sepsis in ICU Patients and Its Correlation with Prognosis.

Authors:  Meini Jiang; Weidong Wu; Xiuzhe Wang; Caixia Zhao
Journal:  Contrast Media Mol Imaging       Date:  2022-09-16       Impact factor: 3.009

Review 2.  Heart Disease and Arboviruses: A Systematic Review and Meta-Analysis.

Authors:  Jandir Mendonça Nicacio; Orlando Vieira Gomes; Rodrigo Feliciano do Carmo; Sávio Luiz Pereira Nunes; José Roberto Coelho Ferreira Rocha; Carlos Dornels Freire de Souza; Rafael Freitas de Oliveira Franca; Ricardo Khouri; Manoel Barral-Netto; Anderson da Costa Armstrong
Journal:  Viruses       Date:  2022-09-08       Impact factor: 5.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.